当前位置: X-MOL 学术Pharmacol. Therapeut. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Regulation of prostate cancer by hormone-responsive G protein-coupled receptors
Pharmacology & Therapeutics ( IF 13.5 ) Pub Date : 2018-06-15 , DOI: 10.1016/j.pharmthera.2018.06.005
Wei Wang , Zhao-Xia Chen , Dong-Yu Guo , Ya-Xiong Tao

Regulation of prostate cancer by androgen and androgen receptor (AR), and blockade of AR signaling by AR antagonists and steroidogenic enzyme inhibitors have been extensively studied. G protein-coupled receptors (GPCRs) are a family of membrane receptors that regulate almost all physiological processes. Nearly 40% of FDA-approved drugs in the market target GPCRs. A variety of GPCRs that mediate reproductive function have been demonstrated to be involved in the regulation of prostate cancer. These GPCRs include gonadotropin-releasing hormone receptor, luteinizing hormone receptor, follicle-stimulating hormone receptor, relaxin receptor, ghrelin receptor, and kisspeptin receptor. We highlight here GPCR regulation of prostate cancer by these GPCRs. Further therapeutic approaches targeting these GPCRs for the treatment of prostate cancer are summarized.



中文翻译:

激素反应性G蛋白偶联受体对前列腺癌的调节

已经广泛研究了雄激素和雄激素受体(AR)对前列腺癌的调节,以及AR拮抗剂和类固醇生成酶抑制剂对AR信号传导的阻断。G蛋白偶联受体(GPCR)是调节几乎所有生理过程的膜受体家族。市场上将近40%的FDA批准的药物靶向GPCR。已经证明多种介导生殖功能的GPCR参与前列腺癌的调节。这些GPCR包括促性腺激素释放激素受体,促黄体生成激素受体,促卵泡激素受体,松弛素受体,生长素释放肽受体和基辛肽受体。我们在这里重点介绍这些GPCR对前列腺癌的GPCR调控。

更新日期:2018-06-15
down
wechat
bug